Human Therapeutics2022-08-26T20:56:22+00:00


There has been significant research into the potential of  Immunoglobulin Y (IgY) as a solution to address some of today’s largest infectious and non-communicable human disease challenges ranging from pandemic preparedness to the realities of antibiotic resistance.


Our pipeline consists of the development of biologic drugs, therapeutics, and nutraceuticals that address some the largest areas of clinical needs.

Universal Influenza Antibody Therapeutic2022-08-08T16:35:14+00:00

Program: IgY-102
Stage: Discovery

Universal influenza IgY nasal spray contains polyclonal antibodies IgY that neutralize a broad spectrum of influenza virus strains including those that cause potential pandemics. The concept is based on the study published in PloS ONE, DOI: 10.1371/journal.pone.0010152

Please contact us to learn more about IGY-102 or to explore partnership opportunities.

Anti-Coronavirus IgY Antibody2022-08-08T16:35:54+00:00

Program: IGY-110
Stage: Preclinical

IGY-110 is an IgY polyclonal antibody targeting the spike proteins of the coronavirus directly via intranasal delivery to the key site of coronavirus entry and infection. Enteric-coated capsules will also be used to help reduce virus activity in the gastrointestinal tract.

The intranasal delivery approach is supported by a recent major scientific publication in the journal Cell, where scientists from the University of North Carolina School of Medicine and the University of North Carolina Gillings School of Global Public Health found that SARS-Co-V2 infects and replicates in the nasal cavity to a greater degree than in cells lower down in the respiratory tract, including the lungs.

IGY-110 is presently in preclinical trials at Health Canada’s National Microbiology Lab in Winnipeg Manitoba.

Please contact us to learn more about IGY-110 or to explore partnership opportunities.

Celiac disease2023-06-05T18:46:35+00:00

Program: IgY-112
Stage: Discovery

IgY for Celiac disease contain polyclonal IgY antibodies that block the interaction of hypersensitive or excessive mucosal immune responses with microbial and protein components that are associated with celiac disease pathogenesis. We are researching the effectiveness of an oral therapeutic using a capsule-based format to deliver the antibodies directly to the small intestine where the inflammation takes place for better management of the disease.

Please contact us to learn more about Celiac disease IgY or to explore partnership opportunities.